

Contents

- Abernethy, D. R., Divoll, M., Greenblatt, D. J., Harmatz, J. S., Shader, R. I.**
Absolute bioavailability of imipramine: influence of food 104
- Ahlenius, S., Larsson, K.**
Lisuride, LY-141865, and 8-OH-DPAT facilitate male rat sexual behavior via a non-dopaminergic mechanism 330
- Amsterdam, J. D., Brunswick, D. J., Potter L., Kaplan, M. J.**
Cimetidine-induced alterations in desipramine plasma concentrations 373
- Anisman, H., Beauchamp, C., Zacharko, R. M.**
Effects of inescapable shock and norepinephrine depletion induced by DSP4 on escape performance 56
- Anisman, H., see Bruto, V., et al.** 62
- Annable, L., see Chouinard, G., et al.** 126
- Antonin, K.-H., see Gleiter, C. H., et al.** 397
- Arnt, J., see Hyttel, J., et al.** 20
- Ba, B., see Viala, A., et al.** 147
- Baker, H. F., see Ridley, R. M., et al.** 340
- Baran, L., see Vetulani, J., et al.** 166
- Barkai, A. I., see Kowalik, S., et al.** 169
- Barkai, A. I., see Reches, A., et al.** 155
- Barratt, N. G., see Ridley, R. M., et al.** 340
- Barrett, J. E., see Brady, L. S., et al.** 151
- Beary, M. D., Lacey, J. H., Crutchfield, M. B., Bhat, A. V.**
Psycho-social stress, insomnia and temazepam: a sleep laboratory evaluation in a "general practice" sample 17
- Beauchamp, C., see Anisman, H., et al.** 56
- Beauchamp, C., see Bruto, V., et al.** 62
- Belmaker, R. H., see Klein, E., et al.** 76
- Berda, C., see Viala, A., et al.** 147
- Berry, M. S., see Smoothy, R.,** 272
- Berry, M. S., see Smoothy, R.** 268
- Bhargava, H. N., see Klein, E., et al.** 76
- Bhat, A. V., see Beary, M. D., et al.** 17
- Bieck, P. R., see Gleiter, C. H., et al.** 397
- Blackburn, T. P., Kemp, J. D., Martin, D. A., Cox, B.**
Evidence that 5-HT agonist-induced rotational behaviour in the rat is mediated via 5-HT₁ receptors 163
- Bowen, D. J., see Grunberg, N. E., et al.** 93
- Bracs, P. U., Gregory, P., Jackson, D. M.**
Passive avoidance in rats: Disruption by dopamine applied to the nucleus accumbens 70
- Braddock, L. E., see Cowen, P. J., et al.** 378
- Bradwejn, J., see Chouinard, G., et al.** 126
- Brady, J. V., see Lukas, S. E., et al.** 316
- Brady, L. S., Valentine, J. O., Barrett, J. E.**
Effects of thyrotropin-releasing hormone (TRH) and a TRH analogue, MK-771, on punished responding of squirrel monkeys 151
- Braestrup, C., see Jensen, L. H., et al.** 249
- Braestrup, C., see Petersen, E. N., et al.** 240
- Broekkamp, C. L., Le Pichon, M., Lloyd, K. G.**
The comparative effects of benzodiazepines, progabide and PK 9048 on acquisition of passive avoidance in mice 122
- Brunswick, D. J., see Amsterdam, J. D., et al.** 373
- Bruto, V., Beauchamp, C., Zacharko, R. M., Anisman, H.**
Amphetamine-induced perseverative behavior in a radial armaze following DSP4 or 6-OHDA pretreatment 62
- Bureš, J., see Burešová, O.** 384
- Burešová, O., Bureš, J.**
Central mediation of the conditioned taste aversion induced in rats by harmaline 384
- Cappell, H., see Greeley, J., et al.** 159
- Carter Snead III, O., see Poldrugo, F.** 140
- Chapman, J. B., Cutler, M. G.**
Sodium valproate: Effects on social behaviour and physical development in the mouse 390
- Chouinard, G., Annable, L., Bradwejn, J.**
An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patient 126
- Cianchetti, C., Masala, C., Olivari, P., Giordano, G.**
Sleep pattern alterations by naloxone. Partial prevention by haloperidol 179
- Concannon, J. T., see Schechter, M. D.** 99
- Cowen, P. J., Braddock, L. E., Gosden, B.**
The effect of amitriptyline treatment on the growth hormone response to apomorphine 378
- Cox, B., see Blackburn, T. P., et al.** 163
- Crutchfield, M. B., see Beary, M. D., et al.** 17
- Cutler, M. G., see Chapman, J. B.** 390
- D'Agostino, N., see Viala, A., et al.** 147
- Dall'Olio, R., see Vaccheri, A., et al.** 28
- Deminière, J. M., Simon, H., Herman, J. P., Le Moal, M.**
6-Hydroxydopamine lesion of the dopamine mesocorticolimbic cell bodies increases (+)-amphetamine self-administration 281
- Depaulis, A., Vergnes, M.**
Gabaergic modulation of mouse-killing in the rat 367
- DeVry, J., Koek, W., Slangen, J. L.**
Effects of drug-induced differences in reinforcement frequency on discriminative stimulus properties of fentanyl 257

- Deviche, P., Schepers, G.**
Ingestive behaviour of the pigeon: Stereoselective influence of the opiate agonist levorphanol and its antagonism by naloxone 357
- Dickson, B. E.,** see Epstein, L. H., et al. 107
- Divoll, M.,** see Abernethy, D. R., et al. 104
- Driscoll, P.,** see Martin, J. R., et al. 262
- Dufour, H.,** see Viala, A., et al. 147
- Durand, A.,** see Viala, A., et al. 147
- Dzoljic, M. R.,** see Ukponmwan, O. E. 229
- Eccleston, D.,** see Frost, S. J., et al. 285
- Ekblom, B., Eriksson, K., Lindström, L. H.**
Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal 293
- Ellinwood, E. H., Nikaido, A., Heatherly, D.**
Diazepam: Prediction of pharmacodynamics from pharmacokinetics 297
- Epstein, L. H., Dickson, B. E., McKenzie, S., Russell, P. O.**
The effect of smoking on perception of muscle tension 107
- Epstein, S.,** see Frieder, B., et al. 51
- Eriksson, K.,** see Ekblom, B., et al. 293
- Fahn, S.,** see Reches, A., et al. 155
- Faldetta, L. L.,** see McNair, D. M., et al. 129
- Faldetta, L. L.,** see McNair, D. M., et al. 134
- Feldman, R. S.,** see McElroy, J. F. 172
- Feldon, J.,** see Shemer, A., et al. 277
- Feldon, J.,** see Weiner, I., et al. 194
- File, S. E.,** see Lister, R. G. 183
- File, S. E.,** see Pellow, S. 304
- Frankenthaler, L. M.,** see McNair, D. M., et al. 129
- Frankenthaler, L. M.,** see McNair, D. M., et al. 134
- Fredricson Overø, K.,** see Hyttel, J., et al. 20
- Frieder, B., Epstein, S., Grimm, V. E.**
The effects of exposure to diazepam during various stages of gestation or during lactation on the development and behavior of rat pups 51
- Frost, S. J., Eccleston, D., Marshall, E. F., Hassanyeh, F.**
Alaproclate - an open clinical study in depressive illness 285
- Furukawa, T.,** see Ushijima, I., et al. 335
- Gaggi, R.,** see Vaccheri, A., et al. 28
- Gandolfi, O.,** see Vaccheri, A., et al. 28
- Garver, D. L.,** see Mavroidis, M. L., et al. 295
- Gentsch, C.,** see Martin, J. R., et al. 262
- Gilliam, P.,** see Spirduso, W. W., et al. 205
- Giordano, G.,** see Cianchetti, C., et al. 179
- Gleiter, C. H., Antonin, K.-H., Bieck, P. R.**
Transdermally applied scopolamine does not impair psychomotor performance 397
- Goldman, C.-P., L.,** see Wilcox, R. E., et al. 48
- Gormezano, I.,** see Schindler, C. W., et al. 114
- Gosden, B.,** see Cowen, P. J., et al. 378
- Greeley, J., Lê, D. A., Poulos, C. X., Cappell, H.**
Alcohol is an effective cue in the conditional control of tolerance to alcohol 159
- Greenblatt, D. J.,** see Abernethy, D. R., et al. 104
- Greenblum, D. N.,** see Mavroidis, M. L., et al. 295
- Gregory, P.,** see Bracs, P. U., et al. 70
- Griffiths, R. R.,** see Lukas, S. E., et al. 316
- Grimm, V. E.,** see Frieder, B., et al. 51
- Grunberg, N. E., Bowen, D. J., Morse, D. E.**
Effects of nicotine on body weight and food consumption in rats 93
- Gualtieri, C. T., Hicks, R. E., Mayo, J. P., Schroeder, S. R.**
The persistence of stimulant effects in chronically treated children: further evidence of an inverse relationship between drug effects and placebo levels of response 448
- Gustafson, L.,** see Hagstadius, S., et al. 321
- Hagstadius, S., Gustafson, L., Risberg, J.**
The effects of bromvincamine and vincamine on regional cerebral blood flow and mental functions in patients with multi-infarct dementia 321
- Hano, J.,** see Vetulani, J., et al. 166
- Harmatz, J. S.,** see Abernethy, D. R., et al. 104
- Harvey, J. A.,** see Schindler, C. W., et al. 114
- Hassanyeh, F.,** see Frost, S. J., et al. 285
- Hatsukami, D. K.,** see Hughes, J. R., et al. 82
- Heatherly, D.,** see Ellinwood, E. H., et al. 297
- Hendry, J. S.,** see Minnema, D. J., et al. 200
- Herman, J. P.,** see Deminière, J. M., et al. 281
- Hicks, R. E.,** see Gualtieri, C. T., et al. 44
- Hillen, F. C.,** see van der Laan, J. W., et al. 213
- Honoré, T.,** see Jensen, L. H., et al. 249
- Honoré, T.,** see Petersen, E. N., et al. 240
- Hou, N.,** see Viala, A., et al. 147
- Hughes, J. R., Hatsukami, D. K., Pickens, R. W., Krahn, D., Malin, S., Luknic, A.**
Effect of nicotine on the tobacco withdrawal syndrome 82
- Hyttel, J., Fredricson Overø, K., Arnt, J.**
Biochemical effects and drug levels in rats after longterm treatment with the specific 5-HT-uptake inhibitor, citalopram 20
- Iversen, S. D.,** see Joyce, E. M. 363
- Jackson, D. M.,** see Bracs, P. U., et al. 70

- Jackson, V.**, see Reches, A., et al. 155
- Jensen, L. H.**, see Petersen, E. N., et al. 240
- Jensen, L. H., Petersen, E. N., Braestrup, C., Honoré, T., Kehr, W., Stephens, D. N., Schneider, H., Seidelman, D., Schmiechen, R.**
Evaluation of the β -carboline ZK93426 as a benzodiazepine receptor antagonist 249
- Jørgensen, A.**, see Viala, A., et al. 147
- Joyce, E. M., Iversen, S. D.**
Dissociable effects of 6-OHDA-induced lesions of neostriatum on anorexia, locomotor activity and stereotypy: The role of behavioural competition 363
- Jungkunz, G., Nedopil, N., Rütger, E.**
Methysergide decreases prolactin release after FK 33-824 [Tyr-D-Ala-Gly-MePhe-Met(o)-ol], a potent analogue of methionine enkephalin. A study in man 210
- Kahn, R. J.**, see McNair, D. M., et al. 129
- Kahn, R. J.**, see McNair, D. M., et al. 134
- Kanter, D. R.**, see Mavroidis, M. L., et al. 295
- Kaplan, M. J.**, see Amsterdam, J. D., et al. 373
- Katsuragi, T.**, see Ushijima, I., et al. 335
- Katz, J. L.**
Effects of clonidine and some α -adrenergic antagonists alone and in combination on schedule-controlled behavior in pigeons and mice 38
- Kehr, W.**, see Jensen, L. H., et al. 249
- Kehr, W.**, see Petersen, E. N., et al. 240
- Kehr, W.**, see Stephens, D. N., et al. 233
- Kemp, J. D.**, see Blackburn, T. P., et al. 163
- Klein, E., Lerer, B., Newman, M., Belmaker, R. H., Bhargava, H. N.**
Effects of cyclo(Leu-Gly) on reserpine-induced hypomotility and increases in cortical β -adrenergic receptors 76
- Koek, W.**, see DeVry, J., et al. 257
- Koek, W., Slangen, J. L.**
Effects of *d*-amphetamine and morphine on delayed discrimination: Signal detection analysis and assessment of response repetition in the performance deficits 346
- Korpi, E. R., Wyatt, R. J.**
Reduced haloperidol: Effects on striatal dopamine metabolism and conversion to haloperidol in the rat 34
- Kowalik, S., Levitt, M., Barkai, A. I.**
Effects of carbamazepine and anti-depressant drugs on endogenous catecholamine levels in the cerebroventricular compartment of the rat 169
- Krahn, D.**, see Hughes, J. R., et al. 82
- Lacey, J. H.**, see Beary, M. D., et al. 17
- Lakić, N.**, see Peričić, D., et al. 79
- Larsson, K.**, see Ahlenius, S. 330
- Lê, D. A.**, see Greeley, J., et al. 159
- Le Moal, M.**, see Deminière, J. M., et al. 281
- Le Pichon, M.**, see Broekkamp, C. L., et al. 122
- Lerer, B.**, see Klein, E., et al. 76
- Levitt, M.**, see Kowalik, S., et al. 169
- Lindström, L. H.**, see Ekblom, B., et al. 293
- Lister, R. G., File, S. E.**
The nature of lorazepam-induced amnesia 183
- Lloyd, K. G.**, see Broekkamp, C. L., et al. 122
- Lubow, R. E.**, see Weiner, I., et al. 194
- Lukas, S. E., Griffiths, R. R., Brady, J. V., Wurster, R. M.**
Phencyclidine-analogue self-infection by the baboon 316
- Luknic, A.**, see Hughes, J. R., et al. 82
- Malin, S.**, see Hughes, J. R., et al. 82
- Manev, H.**, see Peričić, D., et al. 79
- Marshall, E. F.**, see Frost, S. J., et al. 285
- Martin, D. A.**, see Blackburn, T. P., et al. 163
- Martin, J. R., Driscoll, P., Gentsch, C.**
Differential response to cholinergic stimulation in psychogenetically selected rat lines 262
- Masala, C.**, see Cianchetti, C., et al. 179
- Matthies, H.**, see Wetzel, W., et al. 380
- Matthies, H. K.**, see Wetzel, W., et al. 380
- Mavroidis, M. L., Kanter, D. R., Greenblum, D. N., Garver, D. L.**
Adrenergic-receptor desensitization and course of clinical improvement with desipramine treatment 295
- Mayo, J. P.**, see Gualtieri, C. T., et al. 44
- McClelland, G. R., Raptopoulos, P.**
EEG and blood level of the potential antidepressant paroxetine after a single oral dose to normal volunteers 327
- McElroy, J. F., Feldman, R. S.**
Discriminative stimulus properties of fenfluramine: Evidence for serotonergic involvement 172
- McKenzie, S.**, see Epstein, L. H., et al. 107
- McNair, D. M., Kahn, R. J., Frankenthaler, L. M., Faldetta, L. L.**
Amoxapine and amitriptyline. II. Specificity of cognitive effects during brief treatment of depression 134
- McNair, D. M., Kahn, R. J., Frankenthaler, L. M., Faldetta, L. L.**
Amoxapine and amitriptyline. I. Relative speed of antidepressant action 129
- Mello, N. K.**, see Mendelson, J. H. 351
- Mendelson, J. H., Mello, N. K.**
Reinforcing properties of oral Δ^9 -tetrahydrocannabinol, smoked marijuana, and nabilone: Influence of previous marijuana use 351
- Minnema, D. J., Hendry, J. S., Rosecrans, J. A.**
Discriminative stimulus properties of pizotifen maleate (BC105): a putative serotonin antagonist 200

- Montanaro, N.**, see Vaccheri, A., et al. 28
- Mora, F.**, see Shaw, S. G., et al. 288
- Morse, D. E.**, see Grunberg, N. E., et al. 93
- Nedopil, N.**, see Jungkunz, G., et al. 210
- Newman, M.**, see Klein, E., et al. 76
- Nickolson, V. J., van Riesen, H., van Delft, A. M. L.**
Response changes after repeated low apomorphine:
Dopamine autoreceptor desensitization or learning?
188
- Nikaido, A.**, see Ellinwood, E. H., et al. 297
- Olivari, P.**, see Cianchetti, C., et al. 179
- Ott, T.**, see Wetzel, W., et al. 380
- Overstreet, D. H.**, see Wigell, A. H., 88
- Pascoe, P. A., Stone, B. M.**
Ascorbic acid and performance in man 376
- Pellow, S., File, S. E.**
Multiple sites of action for anxiogenic drugs:
Behavioural, electrophysiological and biochemical
correlations 304
- Peričić, D., Lakić, N., Manev, H.**
Effect of diazepam on plasma corticosterone levels
79
- Petersen, E. N.**, see Jensen, L. H., et al. 249
- Petersen, E. N., Jensen, L. H., Honoré, T.,
Braestrup, C., Kehr, W., Stephens, D. N., Wachtel, H.,
Seidelman, D., Schmiechen, R.**
ZK91 296, a partial agonist at benzodiazepine
receptors 240
- Pickens, R. W.**, see Hughes, J. R., et al. 82
- Poldrugo, F., Carter Snead III, O.**
Electroencephalographic and behavioral correlates in rats
during repeated ethanol withdrawal syndromes 140
- Potter L.**, see Amsterdam, J. D., et al. 373
- Poulos, C. X.**, see Greeley, J., et al. 159
- Raptopoulos, P.**, see McClelland, G. R. 327
- Reches, A., Wagner, H. R., Barkai, A. I., Jackson, V.,
Yablonskaya-Alter, E., Fahn, S.**
Electroconvulsive treatment and haloperidol: Effects on
pre- and postsynaptic dopamine receptors in rat
brain 155
- Ridley, R. M., Barratt, N. G., Baker, H. F.**
Cholinergic learning deficits in the marmoset produced by
scopolamine and ICV hemicholinium 340
- Riffée, W. H.**, see Wilcox, R. E., et al. 48
- Risberg, J.**, see Hagstadius, S., et al. 321
- Rosecrans, J. A.**, see Minnema, D. J., et al. 200
- Rüther, E.**, see Jungkunz, G., et al. 210
- Russell, P. O.**, see Epstein, L. H., et al. 107
- Russell, R. W.**
Communication in Psychopharmacology "Asia to the East
of Israel and Turkey" 301
- Sahgal, A.**
A critique of the vasopressin-memory hypothesis 215
- Sansone, M.**, see Vetulani, J., et al. 166
- Schechter, M. D., Concannon, J. T.**
Differential effects of apomorphine in
6-hydroxydopamine-treated and aged rats 99
- Schepers, G.**, see Deviche, P. 357
- Schindler, C. W., Gormezano, I., Harvey, J. A.**
Sensory and associative effects of morphine and
naloxone in classical conditioning of the rabbit
nictitating membrane response 114
- Schmiechen, R.**, see Jensen, L. H., et al. 249
- Schmiechen, R.**, see Petersen, E. N., et al. 240
- Schneider, H.**, see Jensen, L. H., et al. 249
- Schröder, S. R.**, see Gualtieri, C. T., et al. 44
- Seidelman, D.**, see Jensen, L. H., et al. 249
- Seidelman, D.**, see Petersen, E. N., et al. 240
- Shader, R. I.**, see Abernethy, D. R., et al. 104
- Shaw, S. G., Vives, F., Mora, F.**
Opioid peptides and self-stimulation of the medial
prefrontal cortex in the rat 288
- Shearman, G. T.**, see Stephens, D. N., et al. 233
- Shemer, A., Tykocinski, O., Feldon, J.**
Long term effects of chronic chlordiazepoxide
(CDP) administration 277
- Simon, H.**, see Deminière, J. M., et al. 281
- Slangen, J. L.**, see De Vry, J., et al. 257
- Slangen, J. L.**, see Koek, W. 346
- Smoothy, R., Berry, M. S.**
Alcohol increases both locomotion and immobility
in mice: An ethological analysis of spontaneous motor
activity 272
- Smoothy, R., Berry, M. S.**
Effects of ethanol on murine aggression assessed by
biting of an inanimate target 268
- Spiriduso, W. W., Gilliam, P., Wilcox, R. E.**
Speed of movement initiation performance predicts
differences in [³H] spiroperidol receptor binding in
normal rats 205
- Stephens, D. N.**, see Jensen, L. H., et al. 249
- Stephens, D. N.**, see Petersen, E. N., et al. 240
- Stephens, D. N., Shearman, G. T., Kehr, W.**
Discriminative stimulus properties of β -carboline
characterized as agonists and inverse agonists at central
benzodiazepine receptors 233
- Stone, B. M.**, see Pascoe, P. A. 376
- Tykocinski, O.**, see Shemer, A., et al. 277
- Ukponmwan, O. E., Džoljic, M. R.**
Enkephalinase inhibition antagonizes the increased
susceptibility to seizure induced by REM sleep
deprivation 229
- Ushijima, I., Katsuragi, T., Furukawa, T.**
Involvement of adenosine receptor activities in
aggressive responses produced by clonidine in mice 335

- Vaccheri, A., Dall'Olio, R., Gaggi, R., Gandolfi, O., Montanaro, N.**
Antidepressant versus neuroleptic activities of sulpiride isomers on four animal models of depression 28
- Valentine, J. O.,** see Brady, L. S., et al. 151
- Vergnes, M.,** see Depaulis, A. 367
- Vetulani, J., Sansone, M., Baran, L., Hano, J.**
Opposite action of *m*-chlorophenylpiperazine on avoidance depression induced by trazodone and pimozone in CD-1 mice 166
- Viala, A., Hou, N., Ba, B., Durand, A., Dufour, H., D'Agostino, N., Berda, C., Jørgensen, A.**
Blood and plasma kinetics of *cis*(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters 147
- Vives, F.,** see Shaw, S. G., et al. 288
- van Delft, A. M. L.,** see Nickolson, V. J., et al. 188
- van der Laan, J. W., Weick, G., Hillen, F. C.**
Dipropylacetate-induced quasi-morphine abstinence behaviour in the rat: Suppression by α_2 -adrenoceptor stimulation 213
- van Riezen, H.,** see Nickolson, V. J., et al. 188
- Wachtel, H.,** see Petersen, E. N., et al. 240
- Wagner, H. R.,** see Reches, A., et al. 155
- Weick, G.,** see van der Laan, J. W., et al. 213
- Weiner, I., Lubow, R. E., Feldon, J.**
Abolition of the expression but not the acquisition of latent inhibition by chronic amphetamine in rats 194
- Wetzel, W., Ott, T., Matthies, H. K., Matthies, H.**
Effect of the memory-improving substance methylglucamine orotate on paradoxical sleep in rats 380
- Wigell, A. H., Overstreet, D. H.**
Acquisition of behaviourally augmented tolerance to ethanol and its relationship to muscarinic receptors 88
- Wilcox, R. E.,** see Spirduso, W. W., et al. 205
- Wilcox, R. E., Riffes, W. H., Goldman, C.-P., L., Young, R. K.**
Effects of ascorbate on a dopaminergic response: Apomorphine-induced modification of pentylenetetrazol-induced seizures in mice 48
- Willner, P.**
The validity of animal models of depression 1
- Wurster, R. M.,** see Lukas, S. E., et al. 316
- Wyatt, R. J.,** see Korpi, E. R. 34
- Yablonskaya-Alter, E.,** see Reches, A., et al. 155
- Young, R. K.,** see Wilcox, R. E., et al. 48
- Zacharko, R. M.,** see Anisman, H., et al. 56
- Zacharko, R. M.,** see Bruto, V., et al. 62

Indexed in Current Contents

Subject Index

- A**
Acetylcholin 340
Acquisition 114, 281
Activity, peripheral autonomic 134
Activity 390
Adenosine 335
Aggression 268
Aging 99
Alaproclate 285
Alcohol 159
Alpha-adrenergic agents 38
Amitriptyline 129, 134
Amitriptyline 378
Amnesia 183
Amoxapine 129, 134
Amphetamine, chronic 194
Amphetamine 281, 363
Animal models 1
Anorectic drugs 172
Anorexia 363
Anticholinergic activity 129
Antidepressants 11, 104, 126
Anxiety 233, 240, 304
Apomorphine 28, 48, 99, 188, 378
Arousal 107, 215
Ascorbate 48
- Ascorbic acid 376
Ataxia 240
Autoreceptors 155 295
Avoidance, passive 70, 122
Avoidance 166
- B**
Baboon 316
Behavior, aggressive 335
Benzodiazepine 17, 122, 183, 233, 240, 249, 304
Beta-adrenergic receptors 76
Beta-Carbolines 233
Beta-receptors 20
Bicuculline 367
Bioavailability 104
Blood ethanol levels 140
Blood flow, regional cerebral 321
Blood level 147
Blood 285
Body temperature 262
Body weight 93
Bromvincamine 321
- C**
Capacity, reactive 205
- Carbamazepine 169
Catecholamines 169
Cerebellar tremor 384
Cerebroventricular perfusion 169
Chlordiazepoxide 233, 277
Chromodacryorrhea 262
Cigarettes 107
Cimetidine 373
Cis(Z)-clopenthixol decanoate 147
Citalopram 20
Clonidine 38, 335
Clozapine 293
Cocaine 316
Conditional stimuli 159
Conditioning, classical 114
Conditioning, operant 88
Conditioning 159
Conflict 304
Cortex, prefrontal 288
Cortex 76
Crossover design 129, 134
Cyclo(Leu-Gly) 76
Cyprohepatadine 200
- D**
d-Amphetamine 62, 172, 346

- DA receptor sensitivity 188
 Dependence, physical 140
 Depot neuroleptics 147
 Depression 1, 126, 129, 134, 285, 295
 Desimipramine 28, 295
 Desmethylinipramine 169
 Despair, behavioural 28
 Development 99, 390
 Diazepam 51, 79, 233, 297, 335,
 Differential housing 268
 Digit symbol substitution 376
 Discrimination, visual 346
 Disorder, affective 126
 Dopamine nigrostriatal 205
 Dopamine receptors 48
 Dopamine 62, 70, 99, 155, 179, 330,
 363, 378
 DPA 367
 Drinkinh 357
 Drug application, intracerebral 384
 Drug discrimination 99, 172, 233,
 249, 304,
 Drug interactions 373
 Drug self-administration 316
 DSP 4 56, 62
- E**
 EEG, quantitative 327
 EEG withdrawal signs 140
 Effects, cognitive 134
 Efficacy, antidepressant 129
 Enkephalinase inhibition 229
 Enkephalin 210, 288
 Epilepsy 48, 240
 Ergot derivatives 330
 Escape behavior 56
 Ethanol potentiation hypothesis 140
 Ethanol withdrawal syndrome 140
 Ethanol 88, 140, 268, 272
 Exploration 390
- F**
 Feeding 357
 Fenfluramine 172
 Fentanyl 259
 Fluphenazine decanoate 147
 Food consumption 93
 Food interaction 104
- G**
 GABA 367
 Growth hormone 378
 Growth 390
 GVG 367
- H**
 Habituation 188
 Haldol 155
 Haloperidol 28, 34, 179
 Heart rate 107
 Helplessness 28
 Hemicholinium 340
 Humans 17, 44, 82, 104, 107, 126,
 129, 147, 179, 183, 210, 285,
 293, 295, 297, 321, 327, 351, 363,
 367, 373, 376, 378, 397
 Hyperactivity 44, 51
 Hypomotility 28, 76
- Hypothermia 28
- I**
 Imipramine 28, 104, 169
 Immobility 272
 Inhibition, latent 194
 Insomnia 17
 Isomeric specificity 172
- K**
 Ketamine 316
 Ketanserin 163
 Kinetics 297
- L**
 Learning, state-dependent 70
 Learning disabilities 51
 Learning under anesthesia
 Learning 183, 188, 340
 Levorphanol 357
 Locomotion 70, 272, 363
 Long-term treatment 20
 Lorazepam 183
- M**
 Marijuana 351
 Marmoset 340
 Memory, short-term 346
 Memory 122, 183, 215, 340, 380, 384
 Mental functions 321
 Methscopolamine 262
 Methylglucamine orotate 380
 Methylphenidate 44
 Methysergide 163, 210
 Metrazol 277
 Mice 38, 48, 56, 62, 122, 166, 229,
 240, 249, 268, 272, 335, 390
 Mood states 351
 Morphine 114, 257, 288, 346
 Mouse-killing 367
 Movement initiation 205
 Muscarinic cholinergic actions 262
 Muscle tension 107
 m-Chlorophenylpiperazine 166
- N**
 Nabilone 351
 Naloxone 114, 179, 257, 288, 357
 Neophobia 384
 Neostriatum 363
 Neurons, dopaminergic 281
 Nicotine 82, 93
 Norepinephrine 56, 62
 Nucleus accumbens 70
- O**
 Olfactory inferior 384
 Opiates 357
 Opioid peptides 210
 Oxotremorine 262
- P**
 Parkinson's disease 205
 Paroxetine 327
 PCP analogues 316
 Pentylene tetrazol 48
 Perception 107
 Perseveration 62
- Pharmacodynamics 297
 Pharmacokinetics 104, 297
 Phencyclidine 316
 Phosphoramidon 229
 Picrotoxin 367
 Pigeon 38, 357
 Pimozide 166
 Pirenperone 163
 Pizotifen 200
 Plasma corticosterone 79
 Plasma level 147
 Prazosin 38
 Prenatal 51
 Primates 1, 151
 Progabide 122
 Prolactin 210
 Promethazine 200
 Pulse rate 351
 Punished responding 151
- R**
 Rabbit 114
 Rate-dependence 44
 Rats 1, 20, 28, 34, 51, 70, 76, 79, 88,
 93, 99, 140, 155, 159, 163, 169,
 171, 188, 194, 200, 205, 233, 240,
 249, 257, 262, 277, 282, 288, 330,
 346, 380, 384
 REM sleep deprivation 229
 REM sleep 179
 Reaction time 376
 Readdiction 140
 Receptor binding 20
 Receptor, muscarinic 88
 Reinforcement 249, 257
 Reserpine 76
 Resistance
 to extinction 272
 to punishment 272
 Response repetition 346
 Retention 122
- S**
 Saccharin preference 384
 Salivation 262
 Schizophrenia 194, 293
 Scopolamine 262, 340
 Seizures 229
 Selection, psychogenetic 262
 Self-stimulation, intracranial 288
 Serotonin agonists 200
 Serotonin 210
 Sex and strain differences 262
 Sexual behavior 330
 Shock 56
 Sleep, paradoxical 380
 Sleep 179
 Smoking 82
 Social behavior 390
 Social interaction 304
 Speed of onset 129, 134
 Stereoselectivity 357
 Stereotypy 363
 Stimulus, discriminative 200
 Stress 17
 Striatal dopamine mechanisms 34
 Substance withdrawal 82
 Sufentanil 257

Supersensitivity psychosis 293
Supersensitivity 76, 163
Suppression, conditioned 194
Sulpiride isomers 28

T

- Target biting 268
- Temazepam 17
- Temperature 159
- Teratogenicity 390
- THIP 367
- Thyrotropin-releasing hormone 151
- Tolerance, behaviourally augmented 88
- Tolerance, physiological 88

Tolerance 159
Tomoxetine 126
Tranylcypromine 169
Trazodone 166
Tremor 262
Tricyclic antidepressant plasma levels 373
Tube restraint 268

1

Up-regulation 155

v

Valproate 390

Vasopressin 215
Vincamine 321

W

Water consumption 93

Y

Yawning 188
Yohimbine 38

5-HT agonist rotational behavior 163
6-Hydroxydopamine 99
6-OHDA 62

